LDE225 (NVP-LDE225,Erismodegib)

Description: Erismodegib (formerly LDE-225; NVP LDE-225; LDE225; NVP-LDE22; Sonidegib; trade name of Odomzo) is an orally bioavailable small-molecule antagonist of the Smoothened (Smo) in Hedgehog signaling pathway with potential antitumor activity. It inhibits the Hedgehog (Hh) signaling with an IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. As an approved anticancer medication, LDE225 (NVP-LDE225, Erismodegib, Sonidegib) specifically binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, resulting in the suppression of the Hedgehog signaling pathway and thus the inhibition of tumor cell growth in which the Hedgehog pathway is abnormally activated. It is an anticancer drug that received FDA approval in 2015 for the treatment of basal cell carcinoma.

References: Ann Surg. 2011 Nov; 254(5):818-23; ACS Med. Chem. Lett., 2010, 1 (3), 130–134.

Related CAS #: 1218778-77-8 (phosphate); 1799493-22-3 (Sonidegib metabolite M25)